1938 Federal Register / Vol. 77, No. 8 / Thursday, January 12, 2012 / Notices 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and (d) ways to minimize the 

burden of the collection of information 

on respondents, including through the 

use of automated collection techniques 

or other forms of information 

technology. Written comments should 

be received within 60 days of this 

notice. 

Proposed Project 

All Age Influenza Hospitalization 

Surveillance (Flu Hosp)—OMB 0920– 

0806, revision Expiration March 31, 

2012—National Center for 

Immunization and Respiratory Diseases 

(NCIRD), Centers for Disease Control 

and Prevention (CDC). 

Background and Brief Description 

CDC is requesting extension of an 

OMB-approved data collection 

instrument for monitoring laboratoryconfirmed influenza hospitalizations 

(OMB 0920–0806, Exp March 31, 2012). 

Previously, two separate OMB-approved 

tools were used for this project: one for 

pediatric influenza hospitalizations 

(persons <18 years of age) and one for 

adult cases. As many of the same 

questions were asked separately in both 

the pediatric and adult forms, the 

rationale for consolidating these forms 

into one instrument is to minimize 

paperwork at the state/site level. Using 

one collection tool should also decrease 

the likelihood of errors in information 

collection and entry, improve the 

timeliness of data transmission to CDC, 

and minimize the overall burden on 

respondents of information collection. 

The All Age Influenza Hospitalization 

Surveillance (Flu Hosp) project is part 

of the Emerging Infections Program 

(EIP). EIP is a CDC-state-academic 

institution collaborative network 

including California, Colorado, 

Connecticut, Georgia, Maryland, 

Minnesota, New Mexico, New York, 

Oregon and Tennessee. The 

consolidated Flu Hosp information 

collection instrument will be used to 

more efficiently collect demographic 

and clinical information about 

laboratory-confirmed influenza 

hospitalizations among adults and 

children in a geographic- and 

population-defined area of the United 

States. EIP sites will continue collecting 

patient information during the influenza 

season (October 1 of the current year to 

April 30 of the following year) and 

transmit it to CDC on a weekly basis. 

Case reports are submitted as soon as 

possible after case identification and 

investigation. Timely reports to CDC 

allow for rapid identification of 

epidemics, outbreaks and affected 

groups so that preventive measures can 

be quickly taken, and pertinent 

recommendations and policies can be 

made. The Flu Hosp data are also used 

for making influenza vaccination 

recommendations and modeling the 

burden of influenza morbidity and 

mortality. 

The entire data collection instrument 

can be completed from review of the 

hospital medical records. The only 

exception is in regard to the influenza 

vaccination status which, if not 

available in the medical record, may 

involve an interview of the patient or 

patient proxy. Influenza vaccination 

status information is crucial for 

allowing CDC to assess the influenza 

vaccination program performance. 

The respondents for the data 

collection instrument are the Flu Hosp 

participating sites. There are no costs to 

respondents other than their time for 

participating. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

Health Department ............................ All Age Influenza Hospitalization 

Surveillance Project Case Report 

Form.

10 400 15/60 1000 

Total ........................................... ........................................................... ........................ ........................ ........................ 1000 

Dated: January 6, 2012. 

Kimberly Lane, 

Reports Clearance Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. 2012–472 Filed 1–11–12; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60-Day–12–0828] 

Proposed Data Collections Submitted 

for Public Comment and 

Recommendations 

In compliance with the requirement 

of Section 3506(c)(2)(A) of the 

Paperwork Reduction Act of 1995 for 

opportunity for public comment on 

proposed data collection projects, the 

Centers for Disease Control and 

Prevention (CDC) will publish periodic 

summaries of proposed projects. To 

request more information on the 

proposed projects or to obtain a copy of 

the data collection plans and 

instruments, call (404) 639–7570 or 

send comments to Kimberly Lane, CDC 

Reports Clearance Officer, 1600 Clifton 

Road, MS D–74, Atlanta, GA 30333 or 

send an email to omb@cdc.gov. 

Comments are invited on: (a) Whether 

the proposed collection of information 

is necessary for the proper performance 

of the functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and (d) ways to minimize the 

burden of the collection of information 

on respondents, including through the 

use of automated collection techniques 

or other forms of information 

technology. Written comments should 

be received within 60 days of this 

notice. 

Proposed Project 

National Adult Tobacco Survey 

(NATS) (OMB No. 0920–0828, exp. 10/ 

31/2010)—Reinstatement with 

Changes—National Center for Chronic 

Disease Prevention and Health 

Promotion (NCCDPHP), Centers for 

Disease Control and Prevention (CDC) 

and the Center for Tobacco Products 

(CTP), Food and Drug Administration 

(FDA). 


tkelley on DSK3SPTVN1PROD with NOTICES
Federal Register / Vol. 77, No. 8 / Thursday, January 12, 2012 / Notices 1939 

Background and Brief Description 

Tobacco use remains the leading 

preventable cause of disease and death 

in the United States, resulting in 

approximately 440,000 deaths annually. 

Smokers die an average of 14 years 

earlier than non-smokers. Moreover, 

cigarette smoking costs more than $193 

billion; $97 billion in lost productivity 

plus $96 billion in health care 

expenditures. Although the prevalence 

of current smoking among adults in the 

United States has declined significantly 

since 1964, in more recent years (2004 

to 2010) these declines have slowed or 

stalled with 1 in 5 adults reporting 

current smoking. In addition, promotion 

of non-cigarette tobacco products is 

leading to increased diversity of tobacco 

product usage, including the use of 

multiple products. 

With passage of the Family Smoking 

Prevention and Tobacco Control Act 

(FSPTCA) in 2009, the Food and Drug 

Administration is legally mandated to 

regulate tobacco products for the 

protection of public health. Congress 

passed the FSPTCA to discourage 

tobacco use among minors and young 

adults, to encourage cessation among 

adult smokers and to reduce the public 

health burden of tobacco related disease 

in the U.S. Under the Tobacco Control 

Act, FDA has been granted broad 

authority to use the best available 

science to develop and implement 

effective strategies to protect the 

public’s health. FDA authority includes 

setting and enforcing standards for 

tobacco product ingredients and design, 

establishing good manufacturing 

practices, instituting tobacco product 

labeling and health warnings; 

prohibiting marketing that is misleading 

to consumers and developing 

enforcement authorities to act quickly 

and effectively to remove violating 

products. In addition, the FSPTCA gives 

FDA the authority to assert jurisdiction 

over cigars and other currently 

unregulated tobacco products. Finally, 

FDA’s regulatory authority involves 

considering whether the marketing of 

tobacco products might encourage 

people who don’t use tobacco products 

to begin using them, encourage people 

who might otherwise quit to continue 

using tobacco, or encourage former 

users to relapse. 

In order to ensure that FDA is in 

compliance with the Tobacco Control 

Act’s mandate to protect the public 

health, annual data collection is needed 

at least initially to monitor the benefits 

and potential adverse consequences of 

FDA’s regulatory actions, as the 

regulatory framework is being 

established. The FDA must regularly 

monitor patterns of tobacco product 

usage—novel tobacco products as well 

as cigarettes—to identify changes in 

susceptibility and rates of tobacco use 

initiation, perceptions regarding tobacco 

use, and rates of tobacco use cessation. 

Rather than develop a completely new 

system to monitor measures critical to 

FDA, and thereby increasing burden to 

the population, FDA has partnered with 

CDC to leverage the existing NATS 

system. While NATS has been redesigned to meet the critical data needs 

of the FDA, many of the measures are 

relevant to CDC’s National Tobacco 

Control Program (NTCP), and CDC also 

will use the NATS data to evaluate the 

NTCP. Many of the NATS questions 

reflect CDC’s key outcome indicators for 

evaluating tobacco control programs. 

CDC proposes to conduct three annual 

cycles of the National Adult Tobacco 

Survey (NATS) to collect data necessary 

to evaluate the effectiveness of FDA’s 

initial regulatory actions. The NATS 

will be a stratified, random-digit dialed 

telephone survey of noninstitutionalized adults 18 years of age 

and older. To yield results that are 

representative nationally, information 

will be collected from 56,250 landline 

respondents. In addition, to include the 

growing population of households that 

exclusively use cell phones and would 

be missed in a survey relying only on 

land-lines, information will be collected 

from 18,750 cell phone respondents 

who do not have a landline. To obtain 

the target number of completed 

telephone interviews, approximately 

166,000 respondents will be contacted 

for initial eligibility screening. 

Response is voluntary. Study results 

will have significant implications for 

the development and periodic 

adjustment of policies and programs 

aimed at preventing and reducing 

tobacco use in the United States. There 

are no costs to respondents except their 

time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

Adults ages 18 or older .................... Screener for land-line users (pp 67– 

78 of the NATS).

125,000 1 2/60 4,167 

Screener for cell phone users (pp 

79–86 of the NATS).

41,000 1 1/60 683 

National Adult Tobacco Survey (pp 

5–66 of the NATS)—landline.

56,250 1 20/60 18,750 

National Adult Tobacco Survey (pp 

5–66 of the NATS)—cell phone.

18,750 1 20/60 6,250 

Total ........................................... ........................................................... ........................ ........................ ........................ 29,850 

Dated: January 6, 2012. 

Kimberly Lane, 

Reports Clearance Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. 2012–474 Filed 1–11–12; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 


tkelley on DSK3SPTVN1PROD with NOTICES